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Celiac disease is one of the most common food-related chronic disorders in children. Unfortunately, this multifaceted disease is
challenging to recognize and remains markedly underdiagnosed. Screening of either known at-risk groups or even the whole
population could increase the suboptimal diagnostic yield substantially. Many recent guidelines recommend screening of at least
selected risk groups, but more wide-scale screening remains controversial. The increasing prevalence of celiac disease and the
development of autoantibody assays have also led to a gradual shift in the diagnostics towards less invasive serology-based
criteria in a subgroup of symptomatic children. The main open questions concern whether these criteria are applicable to all
countries and clinical settings, as well as to adult patients. On the other hand, widening screening and the mistaken practice of
initiating a gluten-free diet before the appropriate exclusion of celiac disease increase the number of borderline seropositive
cases, which may also challenge the classical histopathological diagnostics. Sophisticated diagnostic methods and a deeper
understanding of the natural history of early developing celiac disease may prove useful in these circumstances.
1. Introduction
With a prevalence of up to 1–3%, celiac disease is one of the
most common chronic gastrointestinal diseases [1–3]. It is
evident that the diagnostics of such a frequent condition
should be eﬀective and practical. Unfortunately, the hetero-
geneous clinical presentation makes the disease diﬃcult to
recognize, and currently the great majority of aﬀected indi-
viduals remain undiagnosed, leaving them vulnerable to
long-term complications [3, 4]. The most eﬀective means of
improving the diagnostic yield would be to screen known
at-risk groups or even the whole population. The develop-
ment of advanced serological tests has made screening rather
straightforward, but the overall beneﬁts of this approach
remain a matter of debate [5]. Particularly controversial
issues are the treatment of asymptomatic screen-detected
individuals, the optimal age for rescreening, the optimal
rescreening frequency, and the utilization of genetic testing
to further delineate the susceptible cohort.
Traditionally, the diagnosis of celiac disease has been
based on the demonstration of mucosal injury in duodenal
biopsy. This invasive approach has been considered neces-
sary to ensure the diagnosis before starting a demanding
gluten-free diet. However, the high speciﬁcity of modern
serological tests and the desire to reduce the need for invasive
investigations led to the release of new criteria by the
European Society for Paediatric Gastroenterology, Hepatol-
ogy, and Nutrition (ESPGHAN) in 2012, which allow for
the ﬁrst time a noninvasive approach to diagnosis in a sub-
group of children [6]. Although a huge leap forward, these
guidelines paradoxically created new challenges, as they are
currently not accepted in all countries and were not drawn
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up for adults [7, 8]. Furthermore, even if the novel approach
was adopted more widely, biopsy would still be needed in
individuals with low positive serology, which are often diag-
nostically the most problematic cases. In fact, the number of
such individuals is likely increasing due to more active
screening.
In this review, we provide an overview of the current
concepts of the diagnostics of celiac disease in children and
adults. The main topics discussed are the possibilities for
improving the suboptimal diagnostic yield and eﬀorts to pro-
vide more uniﬁed diagnostic guidelines in the light of the
most recent scientiﬁc evidence. Furthermore, we discuss the
future directions in diagnostics, particularly concerning early
developing celiac disease with minor or no histopathological
changes and otherwise challenging cases.
2. Diagnostic Approach: From Case Finding
towards Screening
The phenotype of celiac disease extends from varying gastro-
intestinal and extraintestinal complaints to an apparent lack
of symptoms [9]. This variation makes recognition of the
disease challenging, and currently the majority of aﬀected
children and adults remain undiagnosed (Table 1). The main
approaches to detect untreated celiac disease are active case
ﬁnding based on clinical symptoms and signs and targeted
screening of at-risk groups, such as the relatives of celiac dis-
ease patients and subjects with certain other autoimmune
diseases. However, there are major diﬀerences in the diagnos-
tic approach between and even within countries, and this is
also reﬂected in the inconsistencies between the true
population-based prevalence of celiac disease and the num-
ber of actually diagnosed patients (Table 1).
2.1. Case Finding. Case ﬁnding is, in theory, an eﬀective
approach to ﬁnd at least those patients with a characteristic
clinical presentation. However, only those who seek medical
help because of their symptoms or other clinical signs can be
found, which requires activity from the patients themselves.
Furthermore, medical practitioners should be alert to the
possibility of celiac disease behind the various complaints
they encounter in daily practice. Unfortunately, this seems
to be very challenging in the case of celiac disease. It has been
observed that up to 85% of patients eventually found by
screening have suﬀered from unrecognized symptoms for
some time—even for several years—before the diagnosis
[10–14]. The situation is further complicated by the low pre-
dictive value of even “typical” gastrointestinal symptoms for
celiac disease [15, 16].
2.2. Screening: Current Approaches and Open Questions.
There is a clear need for more eﬀective diagnostic approaches
rather than relying on ineﬀective case ﬁnding. The develop-
ment of practical serological tests in recent decades has
enabled easier noninvasive screening, but the matter of who
should be screened is all but clear [5, 17]. Celiac disease ful-
ﬁlls most of the World Health Organization’s general criteria
for screening, but further studies are needed, particularly
regarding the cost-eﬀectiveness of screening and the natural
history of clinically unrecognized patients [17]. The main
issue is whether the beneﬁts of an early diagnosis overcome
the costs, laboriousness, and social burden of a gluten-free
diet [5].
One argument against screening is the low risk for com-
plications in unrecognized celiac disease patients. However,
as already mentioned, many screening-detected subjects
actually suﬀer from unrecognized symptoms. Moreover, even
truly asymptomatic patients might be at risk for ill-health
and long-term complications if left untreated [14, 18–22].
Particularly in children, many complications—such as dental
enamel defects, poor height gain, and reduced bone
accrual—may remain permanent if not detected early enough
[23–25]. Furthermore, if the disease remains untreated until
adulthood, there is an increased risk, e.g., for infertility,
refractory celiac disease, and even small-bowel lymphoma
[26, 27]. Delayed diagnosis may also predispose to reduced
quality of life, the incremental use of medicines, and persis-
tent symptoms even on a gluten-free diet [28, 29].
Table 1: True prevalence of celiac disease based on screening studies and the proportion of clinically unrecognized patients.
Reference and year Country Diagnostic criteria Prevalence (%) Unrecognized (%)
Children
Mäki et al., 2003 [122] Finland Biopsy 1.1 75.9
Tommasini et al., 2004 [123] Italy Biopsy 1.1 94.5
Myléus et al., 2009 [2] Sweden Biopsy 2.9 69.3
Mustalahti et al., 2010 [124] UK Seropositivitya or biopsy 0.9 94.4
Laass et al., 2015 [125] Germany Seropositivitya 0.8 91.7
Adults
West et al., 2003 [126] UK Seropositivitya 1.2 95.7
Lohi et al., 2007 [1] Finland Seropositivitya 2.0 74.9
Mustalahti et al., 2010 [124] Germany Seropositivitya or biopsy 0.3 93.3
Mustalahti et al., 2010 [124] Italy Seropositivitya or biopsy 0.7 97.1
Rubio-Tapia et al., 2012 [127] USA Seropositivitya 0.7 90.1
Fukunaga et al., 2018 [128] Japan Biopsy 0.1 100
aPositive tissue transglutaminase and/or endomysial antibodies.
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A critical aspect regarding the rationale of screening is
the patient’s willingness to adhere to a life-long treatment.
There has been concern that asymptomatic patients in par-
ticular would have poor motivation to maintain the diet
with no apparent clinical beneﬁts. Reported dietary adher-
ence in screen-detected patients has varied from 23% to
93% [12, 14, 30–36]. In more recent studies, the general
tendency has been better adherence, possibly reﬂecting the
increasing knowledge and better availability of gluten-free
products in grocery stores and restaurants [31, 37–41]. In
fact, nowadays even asymptomatic screen-detected patients
may show excellent dietary adherence [14, 42].
The most recent guidelines recommend screening for
celiac disease in selected at-risk individuals (Table 2),
although the actual implementation of the screening in clin-
ical practice varies [43]. However, even with targeted screen-
ing, a substantial percentage of aﬀected individuals will
remain unrecognized [44]. The only option to ﬁnd almost
all celiac disease patients would be to screen the entire
population or, alternatively, subjects with a genetic predis-
position. This approach would still leave the question of
the frequency of repeated screening after negative results,
as celiac disease may develop at any age [2, 45]. Further-
more, wide-scale screening would likely reveal a signiﬁcant
number of seropositive subjects who do not fulﬁll the
current diagnostic criteria. At present, the prognosis and
beneﬁts of the early diagnosis and treatment of such cases
are poorly known [46–51].
3. Changing Guidelines and Development of
Diagnostic Tools
3.1. Histology and Serological Tests. During the past 70 years,
the diagnostics of celiac disease has evolved from symptom-
based deduction to the use of sophisticated serological and
histological methods. The development of biopsy techniques,
followed by the description of duodenal injury, have been
critical milestones [52, 53]. Before the 1970s, histology was
the only diagnostic method in all age groups [54]. A less inva-
sive approach for case ﬁnding could be attained by using
serum antibodies, the ﬁrst of which were antigliadin antibod-
ies with moderate sensitivity and speciﬁcity [55, 56]. More
speciﬁc autoantibodies to reticulin and—particularly from
the 1980s—endomysial antibodies (EmA) proved to be
valuable tools for initial screening [57–59]. The identiﬁcation
of transglutaminase 2 as the autoantigen recognized by EmA
[60] enabled practical ELISA tests for the detection of trans-
glutaminase 2 antibodies (TG2ab) [61].
There have also been improvements in the histopatho-
logical assessment. The original biopsy capsule was gradually
replaced by endoscopic duodenal sampling. In 1992, Marsh
introduced the now widely used grouped classiﬁcation for
histological injury [62], and a modiﬁed version of this
grading was later advocated by Oberhuber [63]. For these
classiﬁcations, the histological injury is divided for practical
purposes into three classes: inﬁltrative (Marsh 1), hyper-
plastic (Marsh 2), and atrophic (Marsh 3) lesions. In the
Oberhuber classiﬁcation, stage 3 is further divided into
subclasses 3a, 3b, and 3c. The more quantitative assess-
ment of the mucosal damage using villous-height crypt
depth measurement was introduced in the early 1980s
and later further improved [64, 65]. At present, however,
this methodology is used mostly in research settings.
3.2. Evolving Guidelines towards a Less Invasive Diagnostic
Approach. With some modiﬁcations, the ESPGHAN 1990
criteria for celiac disease remained the basis of practically
all pediatric and adult diagnostic guidelines until 2012 [6–8,
66–70]. Demonstration of the characteristic histological
lesion, followed by the resolution of symptoms on a gluten-
free diet, allowed the establishment of the diagnosis, with
positive serology giving further support to the diagnosis
[67]. In the early 2000s, the testing of TG2ab came to the
forefront in initial case screenings in both children and
adults, although histological conﬁrmation was still required
[7, 71]. Groups at risk for celiac disease were also increasingly
recognized, and their low-threshold screening was
recommended.
In 2012, the new EPSGHAN diagnostic criteria were
launched [6]. The main driving forces for the revision were
the necessity for general anesthesia for invasive endoscopy
in children and the excellent positive predictive value of
modern serological tests, particularly high tTGab values
(Table 3) and positive EmA. For the ﬁrst time, the revolution-
ary guidelines allowed diagnosis without biopsy in speciﬁc
circumstances; i.e., for symptomatic children with tTGab
values > 10 × the upper limit of normal (ULN), positive
EmA, and the presence of the at-risk human leucocyte anti-
gen (HLA) DQ2/DQ8 haplotype [6]. Recent prospective
studies have provided strong support for the accuracy of
Table 2: Recommendations on screening for celiac disease according to the most recent diagnostic guidelines.
Reference Organization Age group Screening recommendation
Downey et al., 2015 [66] NICE Children and adults T1D, autoimmune thyroidal disease, and family risk
Ludvigsson et al., 2014 [8] BSG Adults T1D, irritable bowel syndrome, Down syndrome, and family risk
Rubio-Tapia et al., 2013 [69] ACG Children and adults Symptomatic T1D and family risk
Husby et al., 2012 [6] ESPGHAN Children
T1D, autoimmune thyroidal and liver diseases, IgA deﬁciency,
family risk, and Down, Turner, and Williams syndromes
Hill et al., 2005 [7] NASPGHAN Children
T1D, autoimmune thyroidal and liver diseases, family risk,
and Down, Turner, and Williams syndromes
ACG: American College of Gastroenterology; BSG: British Society of Gastroenterology; ESPGHAN: European Society for Paediatric Gastroenterology,
Hepatology, and Nutrition; NASPGHAN: North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition; NICE: The National Institute
for Health and Care Excellence; T1D: type 1 diabetes.
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these criteria [72, 73]. There is growing evidence that the
nonbiopsy diagnostic approach could be applied reliably also
for asymptomatic children [74–76] and without mandatory
genetic testing [72]. In adults, histological evaluation has
remained the cornerstone of the diagnosis, excluding the
recently published Finnish guidelines that allow a nonbiopsy
approach in some patients, regardless of their age [68].
4. Challenges with the Diagnostic Criteria and
Future Directions
4.1. Technical Challenges. A major challenge in the current
diagnostics is the lack of standardization in tTGab kits. This
is particularly problematic for the nonbiopsy criteria, as the
resulting incomparability between the assays may even pre-
dispose to misinterpretations [77, 78]. In order to err on
the side of safety, ESPGHAN recommends using only tTGab
tests with an appropriate calibration curve [6]. Furthermore,
the rather high ULN cutoﬀ value and the requirement of
HLA and EmA testing were included partly to control the
assay variation. As mentioned, it might be possible to omit
HLA testing in the future [72], and the role of EmA could
also be questioned. Although EmA is highly speciﬁc, the
required immunoﬂuorescence method is laborious and not
universally available. By applying well-validated tTGab
assays, it might be possible to abandon EmA and also lower
the diagnostic ULN threshold [72, 79].
Histopathology might not be as good a diagnostic refer-
ence standard as previously thought. The mucosal lesion
can be patchy, the quality of the biopsies is often inade-
quate, and duodenal injury is not fully speciﬁc to celiac dis-
ease [80, 81]. In order to improve the diagnostic yield, the
current recommendation is to take at least four biopsies
from the distal duodenum and one from the bulb [6, 66,
82, 83]. However, due to the lower speciﬁcity, the added
value of the duodenal bulb biopsy is controversial, and cau-
tion is needed when a diagnosis of celiac disease is based
solely on bulb samples [84]. In addition, even if representa-
tive biopsies are obtained, their correct handling and orien-
tation are often challenging and prone to mistakes [65].
Accordingly, several studies have shown poor intra- and
interobserver agreement between pathologists when apply-
ing a grouped histological classiﬁcation [85–87].
4.2. Lack of Uniﬁed Guidelines. One of the main challenges
with the current diagnostic criteria is their age- and
country-related variation [6, 8, 69]. Despite the aforemen-
tioned problems, duodenal histopathology as the gold stan-
dard used to be the unifying feature of all the guidelines
[67]. This changed radically when the ESPGHAN criteria
introduced the possibility of omitting endoscopy for some
European children [6], while the biopsy remains mandatory,
e.g., in the USA [7]. These discrepancies might be explained
to some extent by the diﬀerent health care systems [88]. In
addition, most of the studies on this issue have been made
in Europe and, for unclear reasons, studies from North
America have reported the inferior accuracy of tTGab tests
(Table 3). As it is unlikely that children diﬀer signiﬁcantly
between the continents, and since joint guidelines exist for
many other diseases [89, 90], uniﬁed criteria for celiac disease
would seem reasonable.
Another issue is the acceptance of serology-based diagno-
ses of celiac disease in adults by physicians. Only one of the
current guidelines makes a clear statement on this issue; it
does not support the taking of routine duodenal biopsies to
reconﬁrm the diagnosis in adults when the diagnosis has
been set strictly according to the ESPGHAN criteria [91].
This issue is particularly important in the transitional period
from childhood to adulthood, when some young patients
and/or their physicians may question the initial diagnosis
[92]. To avoid confusion and the unnecessary repetition of
diagnostic procedures, general acceptance—or preferably
uniﬁed adult and pediatric criteria—is important.
Recent studies have given evidence that the nonbiopsy
criteria would apply also to adults [79, 93, 94], but many
experts remain cautious [95, 96]. One fear is the misuse of
Table 3: Studies assessing the positive predictive value (PPV) of high tissue transglutaminase antibody (tTGab) values in the diagnosis of
celiac disease.
Reference Cohort Country tTGab threshold Number of tested assays PPV (%)
Children
Paul et al., 2018 [76] 157 UK 10x ULN 1b 100
Werkstetter et al., 2017 [72] 707 Multicenter 10x ULN 8 99.6–100c
Wolf et al., 2017 [73] 898 Germany 10x ULN 1 98.8
Smarrazzo et al., 2017 [129] 1,974 Multicenter 10x ULN 8 96.1
Elitsur et al., 2017 [88] 240 USA 10x ULN 1b 87.7
Trovato et al., 2015 [75] 286 Italy 10x ULN 1 91.0–92.5
Gidrewicz et al., 2015 [130] 17,505 Canada 10x ULN 1 92.8
Adults
Efthymakis et al., 2017 [93] 234 Italy 10x ULN 2 97.6
Ganji et al., 2016 [131] 299a Iran 10x ULN 1 100
Tortora et al., 2014 [101] 310 Italy 8.9x ULN 1 100
aAdults and adolescents. btTGab assay was not speciﬁed. cLowest obtained speciﬁcity when testing diﬀerent diagnostic scenarios and excluding inconclusive
patients. ULN: upper limit of normal; ND: no data.
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the criteria by general practitioners [96–98]. However, there
is evidence that accurate diagnostics can be achieved by edu-
cation and close collaboration with primary care [94, 99].
Another feared consequence of omitting endoscopies is miss-
ing a coexisting disease or complication, such as refractory
celiac disease or malignancy [93, 96]. In practice, however,
this does not seem to be a major problem, although more evi-
dence is called for [79, 93, 100, 101]. In general, the new
guidelines do not aim to ban biopsies, but rather to oﬀer
the option for diagnosis without endoscopy in deﬁnite cases
[6]. Endoscopy would still be preferable if red ﬂag symptoms
such as bloody stools, dysphagia, or severe weight loss
appear, or if there is incomplete clinical recovery [6, 79, 101].
4.3. Challenging Diagnostic Scenarios. Despite the tendency
towards less invasive approaches, duodenal biopsy will likely
remain a part of celiac disease diagnostics for quite some
time. The main problem with serology is that the speciﬁcity
decreases with lower antibody values [72, 79]. Unfortunately,
such patients are usually also histologically the most prob-
lematic cases, as they may present only with mild or patchy
duodenal changes [46, 80]. In these circumstances, it is
important to conﬁrm that all stages of duodenal sampling
and histological analysis have been done correctly [65, 102].
The more quantitative measurement of architectural
changes, e.g., by applying validated duodenal histomorpho-
metry, might also prove useful [65].
The widening use of screening can be expected to
increase the number of patients detected with early stage
celiac disease and morphologically normal villi [46, 49, 103].
There is evidence that seropositive individuals may suﬀer
from symptoms and signs already at this point and beneﬁt
from a gluten-free diet [46, 49, 50, 104], indicating that
the whole deﬁnition of celiac disease might require reeval-
uation. Nevertheless, many such individuals are asymp-
tomatic and do not develop duodenal lesions even
during a long-term follow-up [49, 105–107]. It is essential
to learn more about the natural history of early developing
celiac disease in order to discern cases that would truly
beneﬁt from early diagnosis [108].
Another challenge in the diﬀerential diagnosis of
patients with borderline or negative serology is brought
by the now common practice of initiating a gluten-free diet
before appropriate diagnostic investigations [109, 110]. It
still might be possible to establish the diagnosis using
sophisticated techniques, e.g., determination of small-
bowel mucosal γδ+intraepithelial lymphocytes and celiac
disease-speciﬁc tTG-targeted IgA deposits [46, 111–114].
Genetic testing and recently introduced innovative
methods, such as HLA-DQ-gluten tetramer-based assays,
might further help to exclude or conﬁrm the presence of
celiac disease [115].
4.4. Prevention of Celiac Disease? In the future, it might
even be possible to proceed a step further, as several ongo-
ing prospective birth cohort studies are steadily providing
a deeper understanding of the early development of celiac
disease [116–120]. Increasing information about the dis-
turbed balance of genetics and environmental factors in
celiac disease might oﬀer possibilities for the early detec-
tion of high-risk children, and perhaps even provide
means for primary prevention [116–119, 121].
5. Conclusions
Owing to the high prevalence of celiac disease, even minor
changes in the diagnostic approach may have substantial
eﬀects on health care and society. It is evident that the
only eﬀective way to improve the currently unsatisfactory
diagnostic yield is more widespread screening. Such an
approach could be expected to prevent ill-health and
severe complications in the long run, but it must be
backed up with high-quality scientiﬁc evidence. Eﬀective
implementation of intensiﬁed case ﬁnding and screening
also requires close collaboration with primary care and
general practitioners, who are responsible for the ﬁrst-
line diagnostics.
Simultaneously with the increasing prevalence, the diag-
nostic criteria of celiac disease are currently undergoing rev-
olutionary changes. At present, the serology-based diagnosis
is limited to a minority of patients—i.e., mainly to symptom-
atic European children. This may cause problems, e.g., in the
acceptance of the diagnosis in diﬀerent countries and after
the transition from pediatric to adult care. Since there is no
apparent biological reason for the age- and site-related diﬀer-
ences in the criteria, it would be desirable for more uniﬁed
evidence-based global guidelines for celiac disease to be
formed.
Notwithstanding the increasing tendency towards non-
invasive diagnostics, biopsy will likely play an important
role also in the future, particularly in individuals with
low and/or borderline positive serology. In fact, the num-
ber of these cases will likely increase signiﬁcantly concur-
rently with the widening screening and earlier testing.
Novel sophisticated diagnostic tools may oﬀer better possi-
bilities for diﬀerential diagnosis in these often challenging
situations. Open questions and issues remain concerning
the natural history of these often asymptomatic individ-
uals, particularly whether they should be diagnosed and
treated with a gluten-free diet.
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